The Avastin Dilemma: Two Personalities and Two Points of View on Cost Effectiveness

Two of the key figures in the 2009 health reform debate, Zeke Emanuel and Billy Tauzin, each use Genentech's Avastin to demonstrate the importance of doing cost effectiveness right. But they look at the same drug from very different points of view. Their perspectives provide a good guide to what is at stake in the design of federal approach to comparative effectiveness research.

By Michael McCaughan

When Pharmaceutical Research & Manufacturers of America CEO Billy Tauzin talks about the dangers of government-run cost effectiveness systems, he...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

More from Pink Sheet

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By 

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.